{
  "schema_version": "pdp_json_v1",
  "peptide": {
    "canonical_name": "Secretin",
    "short_name": "Secretin",
    "aliases": [],
    "classification": {
      "category": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
      "needs_prescription": false,
      "notes": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon."
    },
    "status": {
      "category": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
      "jurisdiction": "GLOBAL",
      "last_reviewed": "2026-01-20",
      "human_use_note": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon."
    },
    "structure": {
      "sequence_oneletter": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
      "amino_acid_seq": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
      "molecular_formula": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
      "molecular_weight": null,
      "structure_image_url": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon."
    },
    "risk": {
      "current_score": 5,
      "severity": "moderate",
      "likelihood": "possible",
      "evidence_grade": "unknown",
      "developmental_risk": true,
      "unknowns_penalty": true,
      "rationale": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
      "risk_score": 5
    },
    "sections": {
      "overview": [
        {
          "claim_type": "overview",
          "title": "What it is",
          "population_group": "general",
          "confidence": "unknown",
          "evidence_grade": "unknown",
          "text": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
          "evidence_refs": []
        }
      ],
      "use_cases": [],
      "mechanism": [],
      "human_effects": [],
      "preclinical_effects": [],
      "hypothesized_effects": [],
      "time_dynamics": [],
      "risks": [],
      "contraindications": [],
      "monitoring": [],
      "observed_exposure_ranges": [
        {
          "route": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
          "unit": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
          "min": null,
          "max": null,
          "frequency": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
          "duration": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
          "population_group": "general",
          "notes": "Descriptive only. Observed in studies; not instructions.",
          "evidence_refs": []
        }
      ],
      "developmental_risk_block": [
        {
          "claim_type": "risk",
          "population_group": "adolescent",
          "confidence": "unknown",
          "evidence_grade": "unknown",
          "text": "Developmental risk is flagged due to limited adolescent data and uncertain long-term effects. Endocrine, growth, neurodevelopmental, and metabolic setpoints may be sensitive to perturbation. This section is descriptive only; uncertainty is explicitly acknowledged.",
          "evidence_refs": []
        }
      ],
      "interaction_summary": [],
      "current_outlook_bullets": [
        "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
        "general recovery and resilience interest (anecdotal)",
        "common biohacker curiosity due to community reports",
        "interest in mechanisms suggested by early evidence",
        "used in goal-based stacking discussions (anecdotal)",
        "exploration in wellness communities despite evidence limits"
      ]
    },
    "evidence": [
      {
        "id": "E1",
        "title": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
        "source_type": "pubmed",
        "source_id": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
        "url": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
        "published_date": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
        "evidence_grade": "unknown",
        "notes": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon."
      }
    ],
    "changelog": [
      {
        "date": "2026-01-20",
        "change_type": "initial_entry",
        "summary": "Initial canonical entry for Secretin",
        "detail": "Generated from queue ingestion (Phase 6). Requires human-authored, evidence-bounded content.",
        "evidence_refs": []
      }
    ],
    "meta": {},
    "topics": {
      "primary": [
        "topic_gut_inflammation"
      ]
    },
    "slug": "secretin"
  },
  "interactions": {
    "drug_classes": [],
    "supplement_classes": [],
    "peptides": []
  },
  "practical": {
    "bottom_line": "Secretin is a GI hormone used clinically in diagnostic testing and studied in pancreatic and bile physiology. It is not a wellness peptide; non-medical use can trigger significant GI symptoms.",
    "benefits": [
      "clinical/diagnostic relevance in pancreatic function testing (supervised use)",
      "physiology relevance in bicarbonate secretion and bile/pancreatic signaling"
    ],
    "side_effects_common": [
      "nausea",
      "abdominal discomfort or cramping",
      "flushing",
      "lightheadedness"
    ],
    "side_effects_serious": [
      "severe abdominal pain with persistent vomiting",
      "fainting or collapse",
      "severe allergic reaction symptoms (hives, facial swelling, trouble breathing)"
    ],
    "who_should_be_cautious": [
      "people with significant GI disease or unexplained severe abdominal pain",
      "people with cardiovascular instability or frequent fainting",
      "pregnant or breastfeeding individuals",
      "adolescents (high consequence plus inappropriate for non-clinical use)"
    ],
    "schema_version": "practical_block_v1"
  }
}
